- Home
- GNPX vs CJET Comparison
GNPX vs CJET Comparison
Compare GNPX & CJET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- CJET
- Stock Information
- Founded
- GNPX 2009
- CJET 2009
- Country
- GNPX United States
- CJET China
- Employees
- GNPX N/A
- CJET N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- CJET Auto Manufacturing
- Sector
- GNPX Health Care
- CJET Consumer Discretionary
- Exchange
- GNPX Nasdaq
- CJET Nasdaq
- Market Cap
- GNPX 5.5M
- CJET 4.8M
- IPO Year
- GNPX 2018
- CJET N/A
- Fundamental
- Price
- GNPX $0.31
- CJET $0.13
- Analyst Decision
- GNPX
- CJET
- Analyst Count
- GNPX 0
- CJET 0
- Target Price
- GNPX N/A
- CJET N/A
- AVG Volume (30 Days)
- GNPX 23.7M
- CJET 5.6M
- Earning Date
- GNPX 08-14-2025
- CJET 09-23-2025
- Dividend Yield
- GNPX N/A
- CJET N/A
- EPS Growth
- GNPX N/A
- CJET N/A
- EPS
- GNPX N/A
- CJET N/A
- Revenue
- GNPX N/A
- CJET $6,915,000.00
- Revenue This Year
- GNPX N/A
- CJET N/A
- Revenue Next Year
- GNPX N/A
- CJET N/A
- P/E Ratio
- GNPX N/A
- CJET N/A
- Revenue Growth
- GNPX N/A
- CJET N/A
- 52 Week Low
- GNPX $0.14
- CJET $0.11
- 52 Week High
- GNPX $3.97
- CJET $3.50
- Technical
- Relative Strength Index (RSI)
- GNPX 69.58
- CJET 21.15
- Support Level
- GNPX $0.20
- CJET $0.11
- Resistance Level
- GNPX $0.40
- CJET $1.78
- Average True Range (ATR)
- GNPX 0.04
- CJET 0.13
- MACD
- GNPX 0.02
- CJET -0.09
- Stochastic Oscillator
- GNPX 61.56
- CJET 1.22
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the development, manufacture, sales, and service of new energy vehicles (NEV), hybrid vehicles and traditional fuel vehicles in China. New energy vehicles refer to plug-in electric vehicles, including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans. The company generates all of its revenue from PRC.